Spotlight On... Swiss researchers developing implant to prevent Alzheimer's disease; U.K. startup gets FDA nod for 3-D imaging breath detection; LIM Innovations gets Medicare reimbursement; and more...

Researchers at École Polytechnique Fédérale De Lausanne in Lausanne, Switzerland have developed the prototype of an implant that could prevent Alzheimer's disease by releasing a steady of flow antibodies into the bloodstream. The antibodies then target plaque associated with the disease, and the device has shown promise in mice. More

@FierceMedDev: GE Healthcare hand-held ultrasound in pilot NHS test, $20M Nigerian health initiative. Article | Follow @FierceMedDev

@VarunSaxena2: The chart is just so darn startling/horrible. (Have mentioned it in stories about opioid abuse-deterrent tech.) More from the NYT | Follow @VarunSaxena2

> Cambridge, U.K.-based PneumaCare has received FDA clearance for its Thora-3DI imaging device to measure breathing via detection of chest and abdomen movement. More

> San Francisco-based LIM Innovations said its prosthetic socket, Infinite Socket, has been granted coverage by Medicare. More

> Alere noted that its anticoagulation monitoring test has issues with INR measurement that could lead to rare, but serious, adverse events. But that a recent study found no difference in rate of adverse events in patients with or without the test. More

Biotech News

@FierceBiotech: FierceBiotech Radio on GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster. More | Follow @FierceBiotech

@JohnCFierce: Too bad, if so. $SFY has a beautiful building in Paris. And after its recent Gallic eruption, Paris looks like home. Story | Follow @JohnCFierce

> BerGenBio secures a $25M capital raise for its first-in-class cancer drug. Story

> Lilly CEO's Korean tour sparks rumors of a biosimilars deal with Samsung. Article

> What's next for Gilead in oncology? More

Pharma News

@FiercePharma: UPDATED: Nasdaq exec says biotechs prime Asian unicorns for listings. More from FiercePharmaAsia | Follow @FiercePharma

@EricPFierce: First came the recall, then the FDA plant ban, now the warning letter to Emcure plant for faking data. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: J&J chief Gorsky suffers cuts in bonus, incentive pay, but still racks up $23.8M. News | Follow @CarlyHFierce

> Sanofi CEO considers moving HQ out of Paris to cut costs. Story

> Senators lambaste Turing for 'unethical' price hikes at latest drug price hearing. Article

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.